Epigenomics Deal Gives Roche Access To DNA Methylation Cancer Tests
This article was originally published in The Gray Sheet
Executive Summary
Roche can expect to have DNA methylation-based cancer screening assays available to reference labs by 2006 under a collaboration with Epigenomics
You may also be interested in...
Affymetrix GeneChip Arrays Elevated In Roche Pact, Considered By FDA
Affymetrix' plans to establish its GeneChip as the standard platform technology for genomics-based diagnostics are bolstered by FDA enthusiasm for the probe microarrays, the company claims
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.